The re-usable head tracker is here!
New for Nexstim NBS 6 therapy and research applications
With the new re-usable head tracker license for NBS 6, NBS White Head Trackers may be re-used on a case-by-case basis.
For pre-procedural brain mapping, we recommend to always use a new head tracker. For therapy and research purposes, the adhesive sticker between the head tracker and the patient's forehead can be replaced with designated replacement head tracker stickers from Nexstim.
The advantages of the re-usable license:
- Help us reduce plastic waste and shipping, while you save costs on consumables.
- Harness Nexstim nTMS accuracy and precision for therapy delivery and to control for stimulation variables in your research, without needing to budget consumables.
- Decide on the optimal license for you based on system use. Upgrade with minimal disruption and maximal usability, benefiting from our NBS 6 user-friendly interface.
You want to learn more? Book a virtual demo with our new NBS 6 device to learn more!
If you are attending any of these events, we look forward to showing you the new head tracker in person:
April 15-16, 2025
IONM course Grosshadern, Munich, Germany
April 25-27, 2026
Duke TMS course, Durham, NC, US
May 11-12, 2026
Arkana IONM Advanced course, Heidelberg, Germany
May 11-13, 2026
Scandinavian Neurosurgical Society, Tampere, Finland
June 4-6, 2026
Clinical TMS Society Annual Meeting, Boston, MA, US
Intended purpose & Indications for use:
Pre-procedural mapping (CE mark, FDA clearance, for information on other regional clearances contact Nexstim):
Intended purpose: NBS 6 is intended to be used for localization and assessment of the motor cortex and motor tract integrity for pre-procedural planning purposes. NBS 6 is intended to be used for localization and assessment of cortical areas of speech function for pre-procedural planning purposes.
Indications for use: NBS 6 is indicated for noninvasive mapping of the primary motor cortex of the brain to its cortical gyrus. NBS 6 provides information that may be used in the assessment of the primary motor cortex for pre-procedural planning. NBS 6 is indicated for noninvasive localizations of cortical areas that do not contain essential speech function. NBS 6 provides information that may be used in pre-surgical planning in patients undergoing brain surgery. Intraoperatively, the localization information provided by NBS 6 is intended to be verified by direct cortical stimulation. NBS 6 is not intended to be used during a surgical procedure. NBS 6 is intended to be used by trained clinical professionals.
Post-operative Rehabilitation (CE mark, for information on other regional clearances contact Nexstim):
Intended purpose: NBS 6 is intended to be used for the treatment of surgically induced new or worsening post-operative motor deficits of the upper limb as an adjunct therapy for motor rehabilitation in adult patients having undergone brain tumor surgery. NBS 6 is intended to be used by trained clinical professionals.
Nexstim NBS 6 is not cleared by the FDA for commercial use of post-operative rehabilitation in the United States, for investigational use only.
Major Depressive Disorder (CE mark, FDA clearance, for information on other regional clearances contact Nexstim):
Intended purpose: NBS 6 is intended to be used for treatment of major depressive disorder (MDD) by targeting and delivering noninvasive repetitive TMS stimulation to the patient's dorsolateral prefrontal cortex.
Indications for use: NBS 6 is indicated for the treatment of Major Depressive Disorder in adult patients who have failed to achieve satisfactory improvement from prior antidepressant medication in the current episode. NBS 6 is intended to be use by trained clinical professionals.
Adolescent Major Depressive Disorder (FDA clearance, for information on other regional clearances contact Nexstim):
Indications for use: NBS 6 is indicated as an adjunct for the treatment of MDD in adolescent patients (age 15-21).
Obsessive-Compulsive Disorder (FDA clearance, for information on other regional clearances contact Nexstim):
Indications for use: NBS 6 is indicated as an adjunct for the treatment of adult patients suffering from obsessive-compulsive disorder (OCD).
Chronic Neuropathic Pain (CE mark, for information on other regional clearances contact Nexstim):
Intended purpose: In adult patients suffering from chronic unilateral neuropathic pain, NBS 6 is intended to provide electric field navigated noninvasive repetitive TMS stimulation as therapy to alleviate pain. NBS 6 is intended to be used by trained clinical professionals.
Indications for use: NBS 6 is indicated for MRI-guided and electric field (or E-field) navigated, noninvasive repetitive TMS stimulation (rTMS) of the motor cortex as therapy to alleviate chronic unilateral neuropathic pain in adult patients. Nexstim NBS 6 is intended to be used by trained clinical professionals.
Nexstim NBS 6 is not cleared by the FDA for commercial use of the treatment of chronic pain in the United States, for investigational use only.
Pre-procedural mapping (CE mark, FDA clearance, for information on other regional clearances contact Nexstim):
Intended purpose: NBS 6 is intended to be used for localization and assessment of the motor cortex and motor tract integrity for pre-procedural planning purposes. NBS 6 is intended to be used for localization and assessment of cortical areas of speech function for pre-procedural planning purposes.
Indications for use: NBS 6 is indicated for noninvasive mapping of the primary motor cortex of the brain to its cortical gyrus. NBS 6 provides information that may be used in the assessment of the primary motor cortex for pre-procedural planning. NBS 6 is indicated for noninvasive localizations of cortical areas that do not contain essential speech function. NBS 6 provides information that may be used in pre-surgical planning in patients undergoing brain surgery. Intraoperatively, the localization information provided by NBS 6 is intended to be verified by direct cortical stimulation. NBS 6 is not intended to be used during a surgical procedure. NBS 6 is intended to be used by trained clinical professionals.
Post-operative Rehabilitation (CE mark, for information on other regional clearances contact Nexstim):
Intended purpose: NBS 6 is intended to be used for the treatment of surgically induced new or worsening post-operative motor deficits of the upper limb as an adjunct therapy for motor rehabilitation in adult patients having undergone brain tumor surgery. NBS 6 is intended to be used by trained clinical professionals.
Nexstim NBS 6 is not cleared by the FDA for commercial use of post-operative rehabilitation in the United States, for investigational use only.
Major Depressive Disorder (CE mark, FDA clearance, for information on other regional clearances contact Nexstim):
Intended purpose: NBS 6 is intended to be used for treatment of major depressive disorder (MDD) by targeting and delivering noninvasive repetitive TMS stimulation to the patient's dorsolateral prefrontal cortex.
Indications for use: NBS 6 is indicated for the treatment of Major Depressive Disorder in adult patients who have failed to achieve satisfactory improvement from prior antidepressant medication in the current episode. NBS 6 is intended to be use by trained clinical professionals.
Adolescent Major Depressive Disorder (FDA clearance, for information on other regional clearances contact Nexstim):
Indications for use: NBS 6 is indicated as an adjunct for the treatment of MDD in adolescent patients (age 15-21).
Obsessive-Compulsive Disorder (FDA clearance, for information on other regional clearances contact Nexstim):
Indications for use: NBS 6 is indicated as an adjunct for the treatment of adult patients suffering from obsessive-compulsive disorder (OCD).
Chronic Neuropathic Pain (CE mark, for information on other regional clearances contact Nexstim):
Intended purpose: In adult patients suffering from chronic unilateral neuropathic pain, NBS 6 is intended to provide electric field navigated noninvasive repetitive TMS stimulation as therapy to alleviate pain. NBS 6 is intended to be used by trained clinical professionals.
Indications for use: NBS 6 is indicated for MRI-guided and electric field (or E-field) navigated, noninvasive repetitive TMS stimulation (rTMS) of the motor cortex as therapy to alleviate chronic unilateral neuropathic pain in adult patients. Nexstim NBS 6 is intended to be used by trained clinical professionals.
Nexstim NBS 6 is not cleared by the FDA for commercial use of the treatment of chronic pain in the United States, for investigational use only.
